RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

  • Another Indian Pharmaceutical Company Hammered by FDA for Data Integrity Issues

    A new Warning Letter from the US Food and Drug Administration (FDA) has called out yet another Indian pharmaceutical manufacturing facility for allegedly tampering with or falsifying its data-the 10th letter to an Indian company in the last year making similar allegations. Background As  Regulatory Focus  has previously explained, FDA has been in the midst of a crackdown against deficient manufacturing practices in India, where inspectors have discovered glari...